Molecular breast cancer subtypes and therapies in a public hospital of Northeastern Brazil by Ana Cláudia de Macêdo Andrade et al.
de Macêdo Andrade et al. BMC Women's Health 2014, 14:110
http://www.biomedcentral.com/1472-6874/14/110RESEARCH ARTICLE Open AccessMolecular breast cancer subtypes and therapies
in a public hospital of Northeastern Brazil
Ana Cláudia de Macêdo Andrade1, Carlos Alberis Ferreira Júnior1, Beatriz Dantas Guimarães1,
Ana Waleska Pessoa Barros1, Gibran Sarmento de Almeida2 and Mathias Weller2*Abstract
Background: The frequencies of molecular breast cancer subtypes vary among different human populations. The
Northeastern region of Brazil has a mixed population of African, Indigenous and European ancestry. This retrospective
study investigated breast cancer subtypes and applied therapies in a public hospital of Northeastern Brazil.
Methods: Data of 633 patients with invasive breast cancer from 2005 to 2011 were obtained from medical records.
Status of hormone receptor (HR), HER2 and Ki67 expression index of 269 out of 633 patients were used to define
subtypes of Luminal A and B, HER2 and triple negative (TN) breast cancer. Expression index of Ki67≥ 14% was applied
to distinguish Luminal A from Luminal B subtypes.
Results: Overall, 185 (68.77%) and 132 (49.07%) patients showed positive hormone receptor (HR+) and positive HER2
(HER2+) tumors. The mean age ranged from 53.33 to 58.25 years for patients with tumors of Luminal B and Luminal A
subtypes, respectively (p = 0.0182). In general, 67.39% of patients with TN tumors aged over 50 and 19.57% aged
between 31 and 40 years (p = 0.0046). The rate of small tumors (T1: ≤ 2.0 cm) varied from 22.73% to 52.46% for TN
and Luminal A subtypes (p = 0.0088). The rate of high graded (G3) tumors was increased for HER2 and TN subtypes
(35.29% and 34.28%) compared to Luminal A and Luminal B subtypes (3.92% and 12.62%), respectively (p < 0.0001).
The five-year survival rate ranged from 92.86% to 75.00%, for Luminal A, HER2 and TN subtypes, respectively (HR:
0.260 to 1.015; 95% CI: 0.043 to 3.594; p = 0.2589). Patients with HER2 positive (HER2+) breast tumors did not
receive immunotherapy and chemotherapy application varied from 54.84% to 86.49% for Luminal A and HER2
subtypes, respectively (p = 0.0131).
Conclusions: The results of this study revealed a high percentage of HER2+ breast tumors and an increased rate
of patients with TN tumors aged over 50 years. This emphasizes the need for establishing immunotherapy as an
additional therapeutic option to improve clinical outcomes for patients with HER2+ tumors and to investigate the
risk factors of TN breast cancer.
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Breast cancer represents a molecular and cellular hetero-
geneous group of diseases with different clinical outcomes
[1]. The gene expression profile revealed that the levels of
Estrogen (ER), Progesterone (PR) hormone receptors (HR)
and HER2 overexpression characterize tumors of different
subtypes, including Luminal A (ER + and/or PR + and* Correspondence: mathiasweller@uepb.edu.br
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article, unless otherwise stated.HER2-), Luminal B (ER + and/or PR + and HER2+),
HER2 overexpressed (ER- PR- HER2+) and triple nega-
tive (TN; ER- PR- HER2-) breast cancer [2-5]. Subtypes
have different prognostic values, and Luminal A and triple
negative tumors show the best and worst outcomes,
respectively [6-9].
It is generally recognized that the risk factors affect
the ER, PR and HER2 expression: Post-menopause state,
high body mass index and increased height, were associated
with positive PR tumors and breastfeeding period equal to
or longer than seven months was negatively associated withoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tive ER breast tumors in African American, Hispanic and
white women, was associated with changing incidence
of obesity and parity [12]. There is considerable con-
troversy regarding the role of ancestry in the etiology
of breast cancer [13]. However, results of previous
studies have indicated that variations of subtypes
among populations of African, Asian and Caucasian
ancestry have also a biological basis [14-16]. Americans
of African ancestry have decreased incidence of breast
cancer, but more frequently, they have aggressive, inva-
sive high- grade TN tumors at younger age with increased
mortality rate when compared to patients of Caucasian
ancestry [13,15,17,18].
In Brazil, the ministry of health launched a public
breast cancer- screening program in the year 2003 and
recommended the participation of women aged 50–69
years [19]. The public “Unified Health System” (Sistema
Único de Saúde; SUS) is financing the screening program
and also radiotherapy and chemotherapy for breast cancer
patients. The Brazilian National Institute of Cancer (INCA)
expected 57,120 new cases for the year 2014 with an
estimated risk of 56.09 cases per 100 thousand women
[19]. In the Northeastern region of Brazil, mortality
rates increased on average 5.3% every year in the last
decade, while it declined slightly in other regions of the
country [20]. The Brazilian population is aging and this
demographic process is the combined result of in-
creased life expectation, mainly in the Northern and
Northeastern regions and decreased birth rates in the
entire country [21]. Demographic development, chan-
ging lifestyle and associated risk factors may explain this
drastic increase in the mortality rate observed in the
Northeastern region. Biological factors could also contrib-
ute to differences observed. Populations from Southern
Brazil have mainly Caucasian ancestry; while a mixed
origin of African, European and Indigenous ancestry is
characteristic of populations in the Northeastern region
[22]. The availability of literature about breast cancer in
Brazil is low [23]. To the present moment, few studies
have focused on risk factors and breast cancer screening,
whereas little is known about molecular breast cancer
subtypes of different Brazilian populations. Patients of
African ancestry had an increased frequency of TN
breast cancer [24]. Another study including patients
with undefined ancestry also reported increased incidence
of the TN subtype [25].
The aim of the present study was to investigate the
frequency of breast cancer subtypes in a population of
Northeastern Brazil of mixed African, European and
Indigenous ancestry. The objective was to analyze as-
sociated clinical and histopathological characteristics
of subtypes and to investigate the currently applied
therapies.Methods
Data sampling
The data sampling protocol was reviewed and approved
by the Brazilian National Research Ethics Committee
(CONEP; Nr.: CEP-UEPB: 0239.0.133.000-12).
Registered data from pathological reports of medical
records were obtained from the “Fundação de Assistência
da Paraíba” (FAP) public hospital of Campina Grande,
Paraíba, Brazil. Patients of the FAP hospital are repre-
sentative for the state of Paraíba, with a population of
mixed African, European and native Indigenous ances-
try. Information about ancestry was obtained by the
self- identification method. Patients were asked if they
have European or any kind of mixed African, Indigenous
and European ancestry.
Registered data were obtained from 633 female patients
with confirmed diagnosis of invasive breast cancer. Data
were sampled between March and November 2013. Data
of in situ breast carcinoma were not sampled. Data from
patients with incomplete immunohistochemistry analysis
of hormone receptor and/or HER2/neu expression were
excluded from the study. Only data from patients with
complete immunohistochemistry analysis were sampled
in the medical record. Furthermore, data obtained from
secondary tumors or lymph node surrogates were also
excluded from the sample. Data were exclusively obtained
from primary tumors before application of any chemo or
radiotherapy. Data of death cases were sampled from 2005
to 2008. Complete information about hormone receptor
(ER and PR), HER2/neu status and Ki67expression was
obtained from 295 out of 633 patients. Data sampling in-
cluded histological type of the primary tumor, its grade,
size, hormonal receptor status (ER, PR), HER2/neu status,
state of lymph nodes and presence or absence of distant
metastases. Furthermore, data regarding age, menopause
state and patients’ ancestry were collected from patho-
logical reports of medical records.
Tumor size and grading
Tumors were classified according to the WHO classifica-
tion of breast tumors and graded with the Elston and Ellis
(EE) histoprognostic grade [26]. Tumor size was catego-
rized according to the American Joint Committee on Can-
cer (AJCC) as follows: T1: ≤ 2.0 cm; T2: > 2.0 cm ≤ 5.0 cm;
T3: > 5.0 cm. Trained pathologists from two private labora-
tories performed the grading and immunohistochemistry
assays of tumor specimens.
Immunohistochemistry
Her2/neu was scored from 0 to 3; 0 = no staining; score
1 = faint, partial membrane staining; score 2 = weak
complete membrane staining in > 10% of cancer cells;
score 3 = intense and complete membrane staining in > 10%
of cancer cells. Cases of score 2 were analyzed with
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with immunohistochemistry scores greater than or equal
to 2 and FISH positive. ER and PR positivity was defined
as any positive nuclear staining in ≥ 1% of tumor cells.
Combinations of hormone receptor (ER, PR), HER2/neu
status and Ki67 expression to define molecular breast can-
cer subtypes were used as follows: Luminal A: ER positive
(ER+) and/or PR positive (PR+), Her2 negative (Her2-)
with Ki67 ≤ 14%; Luminal B: ER positive (ER+) and/or PR
positive (PR+) and Her2 positive (Her2+), and any Ki67;
Luminal B: ER positive (ER+) and/or PR positive (PR+)
and Her2 negative (Her2-), with Ki67 > 14%; Her2 sub-
type: Her2 positive (HER2+), ER negative (ER−) and PR
negative (PR-) with any kind of Ki67 expression; Triple
negative (TN): ER negative (ER-), PR negative (PR-) and
HER2 negative (HER2-) with any kind of Ki67 expression.
There was no distinction between basal-like and
normal-like TN tumor subtypes. Of the 295 data sets,
26 had unspecified molecular subtype with unknown
ER, PR or HER2 expression status. These unspecified
26 samples were excluded. The remaining 269 sampled
data sets were from years 2005 (N = 30), 2006 (N = 40),
2007 (N = 37), 2008 (N = 34), 2009 (N = 36), 2010 (N = 45)
and 2011 (N = 47).
Statistical analyses
All statistical analyses were performed on GraphPad
Prism software version 6 (La Jolla, CA). Chi-Square (χ2)
and Fisher‘s exact test were applied to compare categor-
ical variables. ANOVA and the Kruskal- Wallis test were
applied to compare patients’ age. T-test was applied to
compare pair-by-pair mean age. Cumulative survival
probabilities were calculated through the Kaplan– Meier
method. Survival rates were compared by log-rank
(Mantel-Cox) test. Overall, five-year survival rate was
calculated as the period from the year of diagnosis to
the year of death from any cause.
Results
Registered data of breast cancer patients revealed 269
invasive primary tumors with known ER, PR and HER2
status that belonged to one of the four defined subtypes.
Of these tumors, 179 (66.54%), 152 (56.51%) and 132
(49.07%) were positive for ER, PR and HER2, respectively.
Overall, 185 (68.77%) and 84 (31.23%) patients had posi-
tive (HR+) and negative hormone receptor (HR-) tumors,
respectively. When positive HR status was stratified ac-
cording to age, there was no significant difference between
patients aged ≤50 years (64.60%) and those aged > 50 years
(74.07%) (p = 0.1099).
The majority of 120 (44.61%) tumors were Luminal B,
64 (23.79%) were Luminal A, 39 (14.50%) were HER2
and 46 (17.10%) were TN (Table 1). Patients had mean
age of 55.36 ± 0.82 years and age ranged from 26 to92 years (Table 1). The percentage of patient’s aged 31
to 40 and 41 to 50 years varied from 7.69% (HER2) to
19.57% (TN) and from 10.87% (TN) to 38.33% (Luminal B),
respectively (p = 0.0046; Table 1). Patients with tumors
of Luminal A subtype had an increased mean age of
58.25 ± 1.827 years compared to 53.33 ± 1.153 years of
those with tumors of Luminal B molecular subtype
(p = 0.0182; Table 1). Pre-menopause state tended to
be increased for patients with tumors of Luminal B
(38.89%) and TN (33.33) molecular subtypes compared
to those with tumors of Luminal A (22.73%) and HER2
(26.92%) subtypes (Table 1). However, none of these
differences were significant. Information about ances-
try was obtained from 197 out of 269 patients. Self-
identification did not lead to significant differences
between molecular subtypes: Of 197 patients, 168 (85.28%)
had Caucasian and 29 (14.72%) had mixed ancestry
(p = 0.7646; Table 1).
The highest proportion (52.63%) of tumors ≤ 2 cm
(T1) detected was Luminal A, and the lowest (22.73%)
of TN subtype (p = 0.0088). Intermediate size tumors >
2.0 cm ≤ 5.0 cm (T2) were most frequent (70.45%) in
the TN subtype (Table 2). The size category of Luminal
B tumors was slightly and significantly different from
TN tumors (p = 0.0448; Table 2). Lymph node status
and presence or absence of metastases was not signifi-
cantly different among subtypes (Table 2). However,
the highest percentage (51.35%) of positive lymph node
status was found in the group of patients with TN
tumors (Table 2). High graded (G3) tumors were more
frequent (35.29% and 34.28%) in HER2 and TN sub-
types compared to Luminal A and Luminal B subtypes
(3.92% and 12.62%), respectively, and in the case of low
graded (G1) tumors, the opposite was observed (p < 0.0001;
Table 2). Triple negative tumors showed the highest mean
percentage of Ki67 expressing cells (p < 0.0001; Table 2).
Kaplan- Meier analysis of the five-year survival rate of
Luminal A, Luminal B, HER2 and TN molecular sub-
types were 92.86%, 84.75%, and the latter 75.00% each,
respectively (HR: 0.260 to 1.015; 95% CI: 0.043 to
3.594; p = 0.2589; Figure 1).
Complete data for histological staging were available
for 212 out of 269 breast tumors. The histological stage
of tumors was not significantly different among subtypes
(p = 0.4960; Table 3). TN subtype had a decreased rate
of stage IA tumors (10.26%) and a comparable rate of
stage IV tumors (20.51%) as Luminal A subtype (Table 3).
Of the 269 patients, 260 received chemo, radio and/or
hormone therapy in the hospital (Table 3). The chemother-
apeutic regime included cyclophosphamide, doxorubicin
and fluorouracil. Hormone therapy was based on tamoxifen
and anastrozole. Patients with HER2+ tumors did not re-
ceive Trastuzumab or Pertuzumab- based immunotherapy.
Patients with HER2 subtype tumors received preferentially
Table 1 Molecular breast cancer subtypes by frequency and characteristics of patients (Total number N = 269)
Luminal A Luminal B HER2/neu TN p
N % N % N % N %
64 23.79 120 44.61 39 14.50 46 17.10
Age categories
≤ 30 4 6.25 1 0.83 1 2.56 1 2.17 0.0046
31-40 5 7.81 14 11.67 3 7.69 9 19.57
41-50 10 15.63 46 38.33 8 20.51 5 10.87
51-60 16 25.00 27 22.5 11 28.21 12 26.09
> 60 29 45.31 32 26.67 16 41.03 19 41.30
Mean age in years1
58.25 ± 1.827 53.33 ± 1.153 56.59 ± 2.054 55.63 ± 2.025 0.1075
Menopause state
Pre 10 22.73 28 38.89 7 26.92 10 33.33 0.3027
Post 34 77.27 44 61.11 19 73.08 20 66.67
Missing 20 48 13 16
Ancestry
Mixed 8 16.00 14 15.73 4 16.67 3 8.82 0.7646
Caucasian 42 84.00 75 84.27 20 83.33 31 91.18
Missing 14 31 15 12
1Pair wise comparison of Luminal A and Luminal B: p = 0.0182.
Table 2 Molecular breast cancer subtypes by tumor histopathology (Total number N = 269)
Luminal A Luminal B HER2/neu TN p
N % N % N % N %
Tumor size, cm (T category; T1: ≤ 2.0 cm; T2: > 2.0 cm≤ 5.0 cm; T3: > 5.0 cm)1
T1 32 52.46 49 41.88 14 35.90 10 22.73 0.0803
T2 26 42.62 57 48.72 22 56.41 31 70.45
T3 3 4,92 11 9.40 3 7.69 3 6.82
Missing 3 3 0 2
Lymph node status
Positive 22 43.14 41 40.20 13 41.94 19 51.35 0.7067
Negative 29 56.86 61 59.80 18 58.06 18 48.65
Missing 13 18 8 9
Distant metastases
Positive 9 16.36 14 12.73 6 18.18 8 17.78 0.7922
Negative 46 83.64 96 87.27 27 81.82 37 82.22
Missing 9 10 6 1
Histological grade
Low (G1) 11 21.57 14 13.59 1 2.94 1 2.86 < 0.0001
Inter. (G2) 38 74.51 76 73.79 21 61.77 22 62.86
High (G3) 2 3.92 13 12.62 12 35.29 12 34.28
Missing 14 17 5 11
Ki67 positive cells (%)
Mean 6.05 ± 0.467 36.71 ± 1.819 36.43 ± 4.120 50.38 ± 4.691 < 0.0001
1Pair wise comparison of Luminal A and TN: p = 0.0088; Luminal B and TN: p = 0.0448.
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Figure 1 Cumulative five-year survival by molecular subtype in
127 breast cancer patients of years from 2005 to 2008.
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tients with TN breast cancer, 16 (37.21%) did not receive
any chemotherapy (Table 3). The percentage of patients
who received radiotherapy varied from 79.03% to 97.67%
for Luminal A and TN subtypes, respectively (p = 0.0462;
Table 3). Hormone therapy was applied in 75.81% and
82.20% of patients with tumors of Luminal A and B sub-
types, respectively (p < 0.0001; Table 3).
Discussion
Missing immunohistochemistry assays can be the result
of advanced phase of the disease, excluding the advantage
of any chirurgic intervention. Additionally, patients of theTable 3 Molecular breast cancer subtypes by histological stag
Luminal A Luminal B
(N = 64) (N = 120)
Nr % Nr %
IA 12 26.67 29 29.29
IIA 13 28.89 34 34.35
IIB 8 17.78 16 16.16
IIIA 2 4.44 6 6.06
IIIC 1 2.22 - -




Yes 34 54.84 72 61.02
No 28 45.16 46 38.98
R
Yes 49 79.03 99 83.90
No 13 20.97 19 16.10
Ho
Yes 47 75.81 87 82.20
No 15 24.19 21 17.80
n/a 2 2
n/a = not available.present study had to cover the costs of immunohisto-
chemistry assays on their own as the public FAP hospital
does not offer it and the public health system does not
cover the cost of private laboratories. This may lead low-
income patients not to afford for immunohistochemistry
assays. Originally, 283 data sets with and without HR and
HER2 expression status were obtained from years 2005 to
2008 including 63 (22.26%) death cases within five years.
Immunohistochemistry assays were only available for 22
(34.92%) out of the 63 death cases. In view of the great
amount of missing data, the bias effect on the survival
analysis is very probable and incomplete information rep-
resents a general limitation of this retrospective study.
Furthermore, the intergroup heterogeneity among patients
with tumors of one of the four molecular subtypes may
have accounted for statistical bias of clinical data analysis.
Previous studies have shown that patients with positive
HR (ER + and/or PR+) tumors of Luminal A subtype and
a Ki67 index > 14% have poorer outcomes, compared to
those with Ki67 index ≤ 14% [27]. Furthermore, the out-
come of Luminal A subtype with Ki67 index > 14%, was
comparable to HER2+ tumors of Luminal B subtype. For
this reason, several studies classified Luminal A tumors
with high expression of Ki67 as Luminal B subtype
[27-29]. The present study identified Luminal B subtype
as the most frequent subtype (44.61%). This result ise and applied therapies (Total number N = 212)
HER2 TNBC p
(N = 39) (N = 46)
Nr % Nr %
Stage
6 20.69 4 10.26 0.4960
7 24.14 14 35.90
9 31.03 10 25.64
1 3.45 3 7.69
1 3.45 - -




32 86.49 27 62.79 0.0131
5 13.51 16 37.21
adiotherapy
33 89.19 42 97.67 0.0462
4 10.81 1 2.33
rmone therapy
- - - - <0.0001
37 100.0 43 100.0
2 3
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populations that applied Ki67 index > 14% as criteria to
distinguish Luminal A from Luminal B subtypes [28,29].
The study of El Fatemi (2012) identified Luminal B
subtype for 41.01% of all cases studied [29]. The per-
centage of TN breast tumors observed (17.10%) was
consistent with previous studies that revealed frequen-
cies ranging from 9.00% to 30.60% for different popula-
tions [13,18,30-36].
Results revealed an extraordinary high percentage of
HER + tumors (49.07%), if compared to populations from
Spain (19.50%), China (22.10% and 39.60%), Mali (18.00%),
and Hispanic women living in the United States younger
than 50 years of age (23.50%) [11,15,28,37,38]. Corre-
sponding to this high percentage of HER2+ tumors, re-
sults revealed an increased frequency (14.50%) of HER2
subtype, compared to data obtained for Western Europe
(5.2%), Western Africa (9.00%), Northern Africa (9.20%),
China (9.0% and 13.70%), and Afro-American populations
(10.10%) [11,15,28,29,37,38].
Consistent with other studies, patients aged ≤ 40 had
an increased rate (19.57%) of TN tumors [13,18,34,39].
A high percentage of TN tumors belonged to age groups
from 51 to 60 (26.09%) and > 60 (41.30%) years. Previous
studies with Afro American and Hispanic women living
in the US revealed that 29.50% and 19.40% of TN tu-
mors, respectively, were detected in patients aged over
50 years [15]. Other studies with populations from
Northern and Sub Saharan Africa revealed frequencies
of 35.00% and 44.90% for patients aged over 50 years
with tumors of basal-like subtype, respectively [39,40].
This means that the results of TN tumors indicated an
extraordinary high percentage (67.39%) of patients aged
over 50 years. In general, patients had mean age of
55.36 years, while previous studies reported a mean age
of 51.5 and younger [15,39,40]. This could lead to a bias
in the present data, increasing the rate of TN tumors to-
wards older age groups.
Different studies have shown that patients with tumors
of TN subtype had the lowest mean age [6,34]. In con-
trast, the present study revealed the lowest mean age
of 53.33 years for Luminal B subtype. This was most
obvious for the age group from 41 to 50 years, which
included 38.33% of all patients with tumors of Luminal
B subtype. Other studies that have applied the Ki67
index to define the luminal subtype (A or B) have
shown that the lowest mean age was not found for
patients with TN tumors, but in those with luminal B
tumors, and the highest mean age was found for pa-
tients with luminal A tumors [28,40]. Consistent with
present results, the study of Xue and colleagues (2012)
revealed the highest and lowest rate of pre-menopause
state for Luminal B instead of TN and Luminal A subtypes,
respectively [28].There was no significant difference among subtypes
as a function of ancestry, and many previous studies
revealed associations between breast cancer subtypes
and geographic origin of populations [13,15,17,39]. It
is important to point out that self-identification does
not necessarily reflect real ancestry. On the one hand,
as the population is highly mixed, persons who identify
themselves as Caucasian may also have African and/or
Indigenous ancestry and vice versa. Therefore, the mixture
of populations with different geographic origins may ob-
scure biological differences between them. On the other
hand, the present result has to be interpreted with care, as
there was a very low number of patients with mixed an-
cestry and known HR, respectively, HER2 status (N = 29).
Recent studies have revealed that the increased tumor
size of TN breast tumors was associated with decreased
overall survival and increased recurrence rate [41,42].
Present data have indicated a significant increase in
tumor size of TN breast cancer compared to Luminal A
and B molecular subtypes. This increase was mainly due
to a high rate of intermediate size tumors > 2.0 cm ≤
5.0 cm (T2: 70.45%) and a decrease rate of small size
tumors ≤ 2.0 cm (T1: 22.73%) compared to Luminal A
and B subtypes. This result is consistent with previous
findings that attributed increased tumor size of TN sub-
type also to low and high rates of T1 and T2 categories,
respectively [15,36,40].
Present data about lymph node status and distant me-
tastases did not indicate a clear difference between TN
tumors and other subtypes. Similarly, previous studies
did not identify a clear association between TN subtype
and lymph node status or distant metastasis [27,37,42,43].
Several studies revealed the lowest (34.00%- 52.40%) and
highest percentage (56.00%- 86.70%) of positive lymph
node status for Luminal A and HER2 molecular subtypes,
respectively [13,28,29]. In contrast, another study with
Afro-American and Hispanic women revealed the highest
percentage (60.20%) of positive lymph node status for TN
molecular subtype [15]. Present results also revealed the
highest percentage (51.35%) of positive lymph node status
for TN molecular subtype. Differences among the other
three molecular subtypes were small. Therefore, increased
positive lymph node status of the TN subtype could in-
dicate a real biological difference, whereas a sampling
artifact, due to the low number of data, may obscure
further differences among molecular subtypes.
Tumors of HER2 and TN subtypes were higher graded
(G3: 35.29% and 34.28%) than those of Luminal A and B
subtypes (G3: 3.92% and 12.62%). Additionally, TN tu-
mors had on average a high index of Ki67 positive cells
(50.38%), which is associated with increased aggressive-
ness of TN breast tumors [44]. A high grade and prolif-
eration rate of TN tumors has been reported in many
previous studies [15,28,37,42,43]. In the case of HER2
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have revealed a higher grade of HER2 subtype compared
to Luminal A and B tumors [28,45], but other studies
did not identify this relationship [15,40].
The Brazilian public health system does not cover im-
munotherapy costs for HER2 positive breast cancer. This
may explain the high percentage of patients with HER2
positive breast tumors who received chemotherapy
(86.49%). Brazilian health centers, with few exceptions in
cities like São Paulo and Rio de Janeiro, also do not offer
tests for breast cancer patients to analyze the potential
benefit of chemotherapy. In the present study for example,
at least 128 (47.58%) out of 269 patients had invasive stage
I or II tumors smaller than five centimeters in size with
less than four metastasized lymph nodes. They would have
been eligible for the MammaPrint test [46,47].
Advanced stages of the disease or age could advocate
against chemotherapeutic intervention. Among the 16
(37.21%) TN breast cancer patients who did not receive
chemotherapy, only three had stage IV, 13 had stage IA,
IIA or IIB breast cancers and only five of these aged over
50 years. As chemotherapy is one of the few therapeutic
options for TN breast cancer, it remained unclear why
all these patients received radiotherapy and no chemo-
therapy. Similarly, it was not clear why 15 (24.19%) and
21 (17.80%) patients with positive HR breast tumors of
Luminal A and B molecular subtypes did not receive
hormone therapy.
Conclusions
The application of the Ki67 index > 14% as criteria to
distinguish Luminal A from Luminal B molecular sub-
types lead to an increased frequency of Luminal B breast
cancer. Furthermore, patients with tumors of Luminal B
molecular subtype had the lowest mean age. These re-
sults of breast cancer patients in Northeastern Brazil
were consistent with previous studies with populations
from China and Northern Africa that also applied the
Ki67 index > 14% as criteria. Comparable to previous
findings, tumors of TN molecular subtype were also higher
graded, had high Ki67 expression index and increased size
compared to breast tumors of Luminal A and B molecular
subtype.
In contrast to studies with other populations, the
present results revealed a high rate of patients with TN
tumors aged over 50 years. To date, there are no studies
about the risk factors that increase the frequency of TN
breast cancer in populations from Northeastern Brazil.
Future studies should aim on the identification of such
potential risk factors. This could help to improve on-
going prevention programs to reduce the incidence of
this aggressive form of breast cancer. Furthermore, data
indicated an increased frequency of patients with posi-
tive HER2 and high graded tumors of HER2 molecularsubtype, respectively. These patients did not receive
immunotherapy. This emphasizes the need to improve
positive HER2 breast cancer treatment in Northeastern
Brazil through the application of immunotherapy as
additional therapeutic option. Therapeutic opportunities
could also be further improved through the application of
tests with molecular markers to predict the benefits of
chemotherapy.
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